Study Findings: An open-label Phase 2 study of COMP360 psilocybin treatment for PTSD showed it was well tolerated with no serious adverse events, and resulted in significant and lasting symptom improvement over 12 weeks following a single 25 mg dose.
Need for Innovation: PTSD affects approximately 13 million people in the U.S. annually, with limited treatment options available, highlighting the urgent need for innovative therapies like COMP360 to address this mental health condition.
CMPS
$6.39+Infinity%1D
Analyst Views on CMPS
Wall Street analysts forecast CMPS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMPS is 21.00 USD with a low forecast of 12.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast CMPS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMPS is 21.00 USD with a low forecast of 12.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.590
Low
12.00
Averages
21.00
High
40.00
Current: 6.590
Low
12.00
Averages
21.00
High
40.00
Oppenheimer
Oppenheimer
Perform -> Outperform
upgrade
$15
2025-12-09
Reason
Oppenheimer
Oppenheimer
Price Target
$15
2025-12-09
upgrade
Perform -> Outperform
Reason
Oppenheimer upgraded Compass Pathways to Outperform from Perform with a $15 price target.
Oppenheimer
Oppenheimer
Perform -> Outperform
upgrade
$15
2025-12-09
Reason
Oppenheimer
Oppenheimer
Price Target
$15
2025-12-09
upgrade
Perform -> Outperform
Reason
Oppenheimer upgraded Compass Pathways to Outperform from Perform with a $15 price target. The firm is citing it higher conviction that the company's COMP360 will "lead the revolution of psychedelic medicine" for neuropsychiatry, the analyst tells investors in a research note. COMP360, or psilocybin, should become the first ever FDA-approved classical psychedelic therapy for treatment-resistant depression patients, where the firm sees a $1.5B peak sales opportunity, the firm added.
Citizens JMP
Reni Benjamin
Outperform
initiated
$10
2025-12-03
Reason
Citizens JMP
Reni Benjamin
Price Target
$10
2025-12-03
initiated
Outperform
Reason
Citizens JMP analyst Reni Benjamin initiated coverage of Compass Therapeutics with an Outperform rating and $10 price target. The firm says the company's most-advanced candidate, tovecimig, recently demonstrated a 17% overall response rate in combination with paclitaxel as a treatment for biliary tract cancers versus 5% for the paclitaxel comparison arm in a pivotal Phase 2/3 study. The analyst also believes CTX-10726 "could be a diamond in the rough" for Compass.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$45 -> $40
2025-08-04
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$45 -> $40
2025-08-04
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Compass Pathways to $40 from $45 and keeps a Buy rating on the shares. Compass confirmed that no further development is planned in anorexia nervosa following completion of the Phase 2 trial, the analyst tells investors in a research note. As such, the firm removed the indication from its model post the Q2 report.
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
